Abstract
Patients treated with monoclonal antibodies directed against immunological molecules may be viewed as being similar to patients with primary immunodeficiency (PID) of the corresponding antibody target, with regards to infectious risk. László Maródi and Jean-Laurent Casanova propose that the natural history of PIDs might indicate which infectious diseases should be monitored in patients receiving therapeutic antibodies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wallis, R. S. Curr. Opin. Infect. Dis. 22, 403–409 (2009).
Martin-Mola, E. & Balsa, A. Rheum. Dis. Clin. N. Am. 35, 183–199 (2009).
Desai, S. B. & Furst, D. E. Best Pract. Res. Clin. Rheumatol. 20, 757–790 (2006).
Carson, K. R. et al. N. Engl. J. Med. 361, 816–824 (2009).
Quartier, P. et al. Clin. Infect. Dis. 36, e47–e49 (2003).
Aksoy, S. et al. Leuk. Lymphoma 50, 357–365 (2009).
Casanova, J.-L. & Abel, L. Science 317, 617–619 (2007).
Maródi, L. & Notarangelo, L. D. Nature Rev. Immunol. 11, 851–861 (2007).
Suzuki, T. et al. J. Exp. Med. 205, 2703–2710 (2008).
Martinez-Moczygemba, M. et al. J. Exp. Med. 205, 2711–2716 (2008).
Patel, S. Y. et al. J. Immunol. 175, 4769–4776 (2005).
Kampmann, B. et al. J. Clin. Invest. 115, 2480–2488 (2005).
Ram, R. et al. Leuk. Lymphoma 50, 1083–1095 (2009).
Kimby, E. Cancer Treat. Rev. 31, 456–473 (2005).
Kanbayashi, Y. et al. Eur. J. Haematol. 82, 26–30 (2009).
Kiani-Alikhan, S. et al. Br. J. Haematol. 146, 333–335 (2009).
Padate, B. P. & Keidan, J. Clin. Lab. Haematol. 28, 69–71 (2006).
Carrasco, R. et al. Paediatr. Drugs 6, 137–146 (2004).
Bustamante, J. et al. Curr. Opin. Immunol. 20, 39–48 (2008).
Zhang, S. Y. et al. Immunol. Rev. 226, 29–40 (2008).
Picard, C. et al. The clinical features and outcome of IRAK-4 and MyD88 deficiencies. Medicine (in the press).
Major, E. O. N. Engl. J. Med. 361, 1041–1043 (2009).
Maródi, L. & Casanova, J.-L. Lancet 373, 2179–2181 (2009).
Tóth, B. et al. Mol. Immunol. 46, 2140–2146 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Maródi, L., Casanova, JL. Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?. Nat Rev Immunol 10, 299–300 (2010). https://doi.org/10.1038/nri2764
Issue Date:
DOI: https://doi.org/10.1038/nri2764